Furosemide Sopharma

The exact 10 mg/ml human ampoule is currently registered in Georgia and the EU. An authorised EU veterinary 10 mg/ml injectable product confirms the same strength for dogs and cats, but it does not authorise this exact human product for veterinary use.

Guidelines make parenteral furosemide a central treatment for acute canine CHF and pulmonary oedema; veterinary injectable labels, a 30-dog acute study, a 100-pet hospital series and renal-outcome data give direct support. Bolus and CRI strategies both work, but neither is universally superior.

Rapid parenteral diuresis is well characterised but can produce dehydration, hypotension, azotaemia and electrolyte loss; a canine hospital cohort documents kidney injury risk and the 100-pet series found greater creatinine and protein rises with CRI. Dose and route require close reassessment.

The 10 mg/ml concentration permits straightforward weight-based measurement and IV or IM use, but each ampoule contains only 20 mg, so larger dogs or a CRI may require multiple ampoules, dilution and venous access. This is a clinician-administered hospital presentation.

The exact 10 mg/ml human ampoule is currently registered in Georgia and the EU. An authorised EU veterinary 10 mg/ml injectable product confirms the same strength for dogs and cats, but it does not authorise this exact human product for veterinary use.

Guidelines recommend intravenous furosemide for feline CHF with pulmonary oedema, and authorised injectable labels, direct feline IV PK data and a 100-pet acute hospital series support rapid decongestion. Much of the feline regimen evidence remains consensus or retrospective rather than large controlled trials.

Rapid parenteral diuresis is well characterised but can produce dehydration, hypotension, azotaemia and electrolyte loss. Cats with CHF commonly develop azotaemia, while acute bolus or CRI treatment requires close respiratory, renal, electrolyte, hydration and blood-pressure reassessment.

The 10 mg/ml concentration and 2 ml ampoule permit accurate small feline volumes and IV or IM administration without tablet splitting. Venous access, asepsis, patient stress and rapid-diuresis monitoring still make this a clinician-administered hospital presentation.

The exact 40 mg human product is currently registered in Georgia and another major market. Veterinary 40 mg furosemide tablets are authorised for dogs and cats in the UK and veterinary furosemide tablets are FDA-approved, but neither authorises this exact human brand for veterinary use.

Furosemide is a consensus-standard first-line loop diuretic for canine congestive heart failure, with authorised veterinary labels, direct oral PK/diuretic studies and measurements in dogs with CHF. Response and oral bioavailability vary, and evidence for every non-cardiac oedema cause is less direct.

The safety profile is well characterised, but excessive or poorly monitored diuresis can cause dehydration, hypotension, azotaemia and sodium, potassium or chloride depletion. Renal function, electrolytes, hydration, blood pressure and concurrent nephrotoxic or ototoxic drugs require active review.

A validated half-tablet gives a 20 mg step, which can fit some medium or large dogs but is too coarse for many small patients and for fine titration. Published testing shows that split furosemide tablets can vary; smaller doses need a validated lower-strength or compounded formulation.

The exact 40 mg human product is currently registered in Georgia and another major market. Veterinary 40 mg furosemide tablets are authorised for dogs and cats in the UK and veterinary furosemide tablets are FDA-approved, but neither authorises this exact human brand for veterinary use.

Furosemide is the consensus primary oral diuretic for chronic feline congestive heart failure, supported by authorised veterinary labels and direct feline oral PK data. The consensus evidence level for several feline recommendations is low, absorption is variable and the broad non-cardiac oedema scope is less directly studied.

The safety profile is well characterised, but cats with CHF commonly develop azotaemia during treatment and excessive diuresis can cause dehydration, hypotension and electrolyte depletion. Renal function, electrolytes, hydration, blood pressure and concurrent nephrotoxic or ototoxic drugs require active review.

A typical cat needs a small weight-based dose, while the smallest validated half of this tablet is 20 mg. Informal quartering cannot provide reliable feline titration; use a validated lower-strength veterinary tablet or appropriately compounded liquid instead.